FDA Issues Warning Letter to Azurity Pharmaceuticals
September 25, 2024
September 25, 2024
WASHINGTON, Sept. 25 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Azurity Pharmaceuticals Inc.:
* * *
To: Richard Blackburn, Chief Executive Officer, Azurity Pharmaceuticals, Inc., 8 Cabot Road Woburn, MA 01801, United States, richard.blackburn@azurity.com
Dear Mr. Blackburn:
The U.S. Food and Drug Administration inspected your drug manufacturing facility, Azurity Pharma . . .
* * *
To: Richard Blackburn, Chief Executive Officer, Azurity Pharmaceuticals, Inc., 8 Cabot Road Woburn, MA 01801, United States, richard.blackburn@azurity.com
Dear Mr. Blackburn:
The U.S. Food and Drug Administration inspected your drug manufacturing facility, Azurity Pharma . . .